Idexx Laboratories (IDXX) Stock Forecast & Price Target

Compare

2,106 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IDXX Analyst Ratings

Moderate Buy

7 Buy

3 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Idexx

Laboratories

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IDXX Stock 12 Month Forecast

Average Price Target

$777.22

▲(8.89% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Idexx Laboratories in the last 3 months. The average price target is $777.22 with a high forecast of $830.00 and a low forecast of $700.00. The average price target represents a 8.89% change from the last price of $713.74.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"412":"$412","831":"$831","516.75":"$516.8","621.5":"$621.5","726.25":"$726.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":830,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$830.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":777.22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$777.22</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":700,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$700.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[412,516.75,621.5,726.25,831],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,629.51,644.9323076923076,660.3546153846154,675.776923076923,691.1992307692308,706.6215384615384,722.0438461538462,737.4661538461538,752.8884615384616,768.3107692307692,783.733076923077,799.1553846153846,814.5776923076924,{"y":830,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,629.51,640.8723076923077,652.2346153846154,663.5969230769231,674.9592307692308,686.3215384615385,697.6838461538462,709.0461538461539,720.4084615384616,731.7707692307692,743.1330769230769,754.4953846153846,765.8576923076923,{"y":777.22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,629.51,634.9323076923076,640.3546153846154,645.776923076923,651.1992307692308,656.6215384615384,662.0438461538462,667.4661538461538,672.8884615384616,678.3107692307692,683.733076923077,689.1553846153846,694.5776923076924,{"y":700,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":495.42,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":417.28,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":430.77,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":413.44,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":422.05,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":437.11,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":418.57,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":471.38,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":514.8,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":542.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":535.54,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":620.11,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":629.51,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$830.00

Average Price Target$777.22

Lowest Price Target$700.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrea Alfonso

UBS

$710→$750

Hold

5.08%

Upside

Reiterated

11/04/25

Idexx Laboratories price target raised to $750 from $710 at UBSIdexx Laboratories price target raised to $750 from $710 at UBS

Cira Diagnissa

TR | OpenAI - 4o

$713

Buy

-0.10%

Downside

Reiterated

11/04/25

AI Generated ArticleAI Generated Article

Mark Massaro

BTIG

$785→$830

Buy

16.29%

Upside

Reiterated

11/04/25

Idexx Laboratories: Strong Financial Performance and Strategic Advancements Justify Buy Rating

Erin Wright

Morgan Stanley

$765→$805

Buy

12.79%

Upside

Reiterated

11/03/25

Idexx Laboratories price target raised to $805 from $765 at Morgan StanleyIdexx Laboratories price target raised to $805 from $765 at Morgan Stanley

Ryan Daniels

William Blair

―

Buy

―

Reiterated

11/03/25

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Cullinan Management (NASDAQ: CGEM) and Idexx Laboratories (NASDAQ: IDXX)

Jonathan Block

Stifel Nicolaus

$700→$775

Buy

8.58%

Upside

Reiterated

11/03/25

Idexx Laboratories price target raised to $775 from $700 at StifelIdexx Laboratories price target raised to $775 from $700 at Stifel

Michael Ryskin

Bank of America Securities

$700→$790

Hold

10.68%

Upside

Reiterated

11/03/25

Idexx Laboratories price target raised to $790 from $700 at BofAIdexx Laboratories price target raised to $790 from $700 at BofA

Daniel Clark

Leerink Partners

$745→$785

Buy

9.98%

Upside

Reiterated

11/03/25

Idexx Laboratories price target raised to $785 from $745 at LeerinkIdexx Laboratories price target raised to $785 from $745 at Leerink

Chris Schott

J.P. Morgan

$775

Buy

8.58%

Upside

Reiterated

11/03/25

J.P. Morgan Keeps Their Buy Rating on Idexx Laboratories (IDXX)

Keith Devas

Jefferies

$785

Buy

9.98%

Upside

Reiterated

08/18/25

Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON), Medtronic (NYSE: MDT) and Idexx Laboratories (NASDAQ: IDXX)

David Westenberg

Piper Sandler

$510→$700

Hold

-1.93%

Downside

Reiterated

08/11/25

Piper Sandler Reaffirms Their Hold Rating on Idexx Laboratories (IDXX)

Balaji Prasad

Barclays

$520

Buy

-27.14%

Downside

Reiterated

02/04/25

Barclays Sticks to Its Buy Rating for Idexx Laboratories (IDXX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrea Alfonso

UBS

$710→$750

Hold

5.08%

Upside

Reiterated

11/04/25

Idexx Laboratories price target raised to $750 from $710 at UBSIdexx Laboratories price target raised to $750 from $710 at UBS

Cira Diagnissa

TR | OpenAI - 4o

$713

Buy

-0.10%

Downside

Reiterated

11/04/25

AI Generated ArticleAI Generated Article

Mark Massaro

BTIG

$785→$830

Buy

16.29%

Upside

Reiterated

11/04/25

Idexx Laboratories: Strong Financial Performance and Strategic Advancements Justify Buy Rating

Erin Wright

Morgan Stanley

$765→$805

Buy

12.79%

Upside

Reiterated

11/03/25

Idexx Laboratories price target raised to $805 from $765 at Morgan StanleyIdexx Laboratories price target raised to $805 from $765 at Morgan Stanley

Ryan Daniels

William Blair

―

Buy

―

Reiterated

11/03/25

Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Cullinan Management (NASDAQ: CGEM) and Idexx Laboratories (NASDAQ: IDXX)

Jonathan Block

Stifel Nicolaus

$700→$775

Buy

8.58%

Upside

Reiterated

11/03/25

Idexx Laboratories price target raised to $775 from $700 at StifelIdexx Laboratories price target raised to $775 from $700 at Stifel

Michael Ryskin

Bank of America Securities

$700→$790

Hold

10.68%

Upside

Reiterated

11/03/25

Idexx Laboratories price target raised to $790 from $700 at BofAIdexx Laboratories price target raised to $790 from $700 at BofA

Daniel Clark

Leerink Partners

$745→$785

Buy

9.98%

Upside

Reiterated

11/03/25

Idexx Laboratories price target raised to $785 from $745 at LeerinkIdexx Laboratories price target raised to $785 from $745 at Leerink

Chris Schott

J.P. Morgan

$775

Buy

8.58%

Upside

Reiterated

11/03/25

J.P. Morgan Keeps Their Buy Rating on Idexx Laboratories (IDXX)

Keith Devas

Jefferies

$785

Buy

9.98%

Upside

Reiterated

08/18/25

Analysts Offer Insights on Healthcare Companies: Disc Medicine (NASDAQ: IRON), Medtronic (NYSE: MDT) and Idexx Laboratories (NASDAQ: IDXX)

David Westenberg

Piper Sandler

$510→$700

Hold

-1.93%

Downside

Reiterated

08/11/25

Piper Sandler Reaffirms Their Hold Rating on Idexx Laboratories (IDXX)

Balaji Prasad

Barclays

$520

Buy

-27.14%

Downside

Reiterated

02/04/25

Barclays Sticks to Its Buy Rating for Idexx Laboratories (IDXX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Idexx Laboratories

1 Month

xxx

Success Rate

19/29 ratings generated profit

Average Return

+3.13%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 65.52% of your transactions generating a profit, with an average return of +3.13% per trade.

3 Months

xxx

Success Rate

19/29 ratings generated profit

Average Return

+7.67%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 65.52% of your transactions generating a profit, with an average return of +7.67% per trade.

1 Year

Jonathan BlockStifel Nicolaus

Success Rate

25/29 ratings generated profit

Average Return

+32.99%

reiterated a buy rating 5 days ago

Copying Jonathan Block's trades and holding each position for 1 Year would result in 86.21% of your transactions generating a profit, with an average return of +32.99% per trade.

2 Years

xxx

Success Rate

24/29 ratings generated profit

Average Return

+69.43%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 82.76% of your transactions generating a profit, with an average return of +69.43% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IDXX Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IDXX has received 25 Buy Ratings, 6 Hold Ratings, and 1 Sell Ratings. IDXX average Analyst price target in the past 3 months is 777.22.

Each month's total comprises the sum of three months' worth of ratings.

IDXX Financial Forecast

IDXX Earnings Forecast

Next quarter’s earnings estimate for IDXX is $2.92 with a range of $2.72 to $3.00. The previous quarter’s EPS was $3.40. IDXX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year IDXX has Preformed in-line its overall industry.

IDXX Sales Forecast

Next quarter’s sales forecast for IDXX is $1.07B with a range of $1.04B to $1.08B. The previous quarter’s sales results were $1.11B. IDXX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year IDXX has Preformed in-line its overall industry.

IDXX Stock Forecast FAQ

What is IDXX’s average 12-month price target, according to analysts?

Based on analyst ratings, Idexx Laboratories’s 12-month average price target is 777.22.

What is IDXX’s upside potential, based on the analysts’ average price target?

Idexx Laboratories has 8.89% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IDXX a Buy, Sell or Hold?

Idexx Laboratories has a consensus rating of Moderate Buy which is based on 7 buy ratings, 3 hold ratings and 0 sell ratings.

What is Idexx Laboratories’s price target?

The average price target for Idexx Laboratories is 777.22. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $830.00 ,the lowest forecast is $700.00. The average price target represents 8.89% Increase from the current price of $713.74.

What do analysts say about Idexx Laboratories?

Idexx Laboratories’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of IDXX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Idexx Laboratories (IDXX) Stock Forecast & Price Target

IDXX Analyst Ratings

IDXX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Idexx Laboratories

IDXX Analyst Recommendation Trends

IDXX Financial Forecast

IDXX Earnings Forecast

IDXX Sales Forecast

IDXX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts